C
랩지노믹스
084650KOSDAQ자연과학 및 공학 연구개발업43.0 / 100
Reference Date: 2026-06-10
Financial Score17.5 / 40
News Sentiment12.5 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but Operating Profit is on a declining trend. Declined 7.7% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Labgenomics specializes in genetic molecular diagnostics, including non-invasive prenatal testing (NIPT), cancer gene screening, and chromosomal abnormality detection. As the first company in South Korea to commercialize NIPT, it leads the market with its 'MomGuard' product line and continues to expand its portfolio with innovations like the LabGun COVID-19 assay and early Alzheimer's diagnostic kits.
Number of Employees
142people
Average Salary
49.7M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 62.704.0Point
PBR
0.57Industry Average 3.247.0Point
Half of industry avg (excellent)
ROE
-35.18Industry Average -32.093.5Point
In line with industry avg
Debt Ratio
13.61Industry Average 7.310.5Point
1.9x industry avg (risky)
Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3
Avg ▲10.0% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼180.8% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -16.1% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (14%, downtrend)
Current 1,157Won52-week high 2,86552-week low 864
1-month return1.0Point
1m -7.66% (falling)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
8 totalPositive 0Neutral 8Negative 0
- Neutral주식등의대량보유상황보고서(일반)2026-05-28
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-27
- Neutral[기재정정]임원ㆍ주요주주특정증권등소유상황보고서2026-05-27
- Neutral주식등의대량보유상황보고서(일반)2026-05-26
- Neutral증권발행결과(자율공시)2026-05-20